Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Treatment
Clinical study results build case for expanded use of FUZEON
December 6th, 2004
Earlier use of FUZEON (enfuvirtide) in treatment-experienced HIV patients results in better treatment outcomes and preserves future drug options, according to new data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Washington, D.C. This finding emerged from one of several new presentations at ICAAC on FUZEON, which is comarketed by Roche and Trimeris, Inc., (TRMS). "FUZEON is the first and only drug of its kind, and our knowledge of how it is best used continues to grow," said Dr. Calvin J. Cohen, research director at the Community Research Initiative of New England. "The data presented at...
Source: Obesity & Diabetes Week (2004-12-06)
|
